Erdanat 4 (Erdafitinib Tablets 4 mg) is a prescription oncology medicine manufactured by Natco Pharma, India. Erdafitinib is an FGFR inhibitor used in the treatment of certain types of advanced urothelial cancer with specific genetic alterations.
Product Details
| Product Information | Details |
|---|---|
| Brand Name | Erdanat 4 |
| Generic Name | Erdafitinib |
| Strength | 4 mg |
| Manufacturer | Natco Pharma |
| Dosage Form | Oral Tablets |
| Packaging | 28 Tablets |
| Product Category | Oncology / Anticancer |
| Country of Origin | India |
| Prescription Status | Prescription Only |
Uses of Erdanat 4 (Erdafitinib 4 mg)
Erdafitinib is a targeted cancer medicine used for certain patients with locally advanced or metastatic urothelial carcinoma involving susceptible FGFR3 genetic alterations.
The medicine works by blocking specific FGFR proteins involved in cancer cell growth. It should only be prescribed and monitored by a qualified oncology specialist.
Erdanat 4 Export from India – Target Countries
BizHQ welcomes international pharmaceutical sourcing enquiries from licensed buyers in the following markets:
North America: USA, Canada, Mexico
Europe: UK, Germany, France, Italy, Spain, Netherlands, Poland
Middle East: UAE, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain
Asia: Singapore, Malaysia, Thailand, Philippines, Vietnam, Bangladesh, Nepal, Sri Lanka
Africa: South Africa, Nigeria, Kenya, Ghana, Uganda, Tanzania
Oceania: Australia, New Zealand
South America: Brazil, Chile, Colombia, Peru
Product registration, availability, import permissions, and lawful distribution requirements must be verified separately for each destination.
Why Choose BizHQ – Medicine India Export?
Pharmaceutical sourcing assistance from India
International B2B medicine procurement enquiries
Wholesale order coordination
Assistance with applicable export documentation
Communication support for international buyers
Product availability and quotation enquiries
All transactions are subject to licensing, product verification, and applicable pharmaceutical regulations.
Frequently Asked Questions (FAQs)
1. What is Erdanat 4 used for?
Erdanat 4 contains Erdafitinib, a targeted medicine used for certain patients with advanced urothelial cancer and specific FGFR3 genetic alterations.
2. Who manufactures Erdanat 4?
Erdanat 4 is manufactured by Natco Pharma, India, according to the product packaging.
3. Can I import Erdanat 4 from India?
Importation depends on the destination country's medicine registration, importer licensing, and applicable regulatory approvals.
4. Is Erdanat 4 available for wholesale orders?
Licensed pharmaceutical buyers can enquire about availability, minimum order quantity, and procurement terms.
5. Can I request Erdafitinib 4 mg export pricing?
Yes. Contact BizHQ with your required quantity, destination country, and business details to request a quotation, subject to lawful supply and availability.
6. What is the packaging size of Erdanat 4?
The product packaging shown contains 28 tablets.
7. What documents are required for international pharmaceutical shipping?
Depending on the country, documents may include a commercial invoice, packing list, import permit, pharmaceutical licenses, and batch-specific quality documents.
8. Does BizHQ accept enquiries from international pharmaceutical distributors?
Yes. Licensed pharmaceutical importers, distributors, and healthcare procurement businesses can contact BizHQ for product sourcing information.
Contact BizHQ – Medicine India Export
For Erdanat 4 (Erdafitinib 4 mg) sourcing enquiries, wholesale procurement information, and international pharmaceutical trade enquiries, contact:
🌐 Website: https://www.medicineindiaexport.com/
📧 Email: sales.medindiaexport@gmail.com
📱 WhatsApp: +91 7218129896
BizHQ – Your Partner for International Pharmaceutical Sourcing from India.
 Exporter & Wholesale Supplier from India to USA, UK, Canada, Australia, Germany, France, Italy, Spain, Netherlands, Poland, UAE, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain, Singapore, Malaysia, Thailand, Philippines, Vietnam, Indonesia, Bangladesh, Nepal, Sri Lanka, Maldives, South Africa, Nigeria, Kenya, Ghana, Uganda, Tanzania, Ethiopia, Zambia, Zimbabwe, Egypt, Morocco, Algeria, Mauritius, New Zealand, Mexico, Brazil, Chile, Colombia, Peru, Argentina, Ecuador, Panama, Costa Rica, Turkey, Iraq, Jordan, Israel, Lebanon, Cambodia, Myanmar, South Korea, Japan, Taiwan, Hong Kong, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Romania, Bulgaria, Greece, Portugal, Belgium, Switzerland, Austria, Sweden, Norway, Denmark, Finland, Ireland, Czech Republic, Hungary, Croatia, Serbia, Slovakia, Slovenia, Lithuania, Latvia, Estonia, Ukraine, Pakistan & Global Markets){kind=link}